Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

SUNNYVALE, Calif., July 31, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its quarter ended June 30, 2013.

Financial Results for the Three and Six Months Ended June 30, 2013 Non-GAAP net income reported for the quarter ended June 30, 2013 was $19.2 million, or $0.26 and $0.25 net income per basic and diluted share, respectively, compared to non-GAAP net loss of $15.1 million, or $0.22 net loss per basic and diluted share for the quarter ended June 30, 2012. Non-GAAP net loss reported for the six months ended June 30, 2013 was $9.1 million, or $0.13 net loss per share, compared to non-GAAP net loss of $24.4 million or $0.35 net loss per share for the six months ended June 30, 2012. See "Use of Non-GAAP Financial Measures" below for a description of our non-GAAP measures. Reconciliation between certain generally accepted accounting principles ("GAAP") and non-GAAP measures is provided at the end of this press release.

GAAP net income for the quarter ended June 30, 2013 was $12.4 million, or $0.17 and $0.16 net income per basic and diluted share, respectively. This includes stock-based compensation expense of $6.9 million. For the quarter ended June 30, 2012, GAAP net loss was $16.9 million, or $0.24 net loss per share. This includes stock-based compensation expense of $1.8 million. For the six months ended June 30, 2013, GAAP net loss was $39.6 million, or $0.55 net loss per basic and diluted share, compared to GAAP net loss of $29.7 million, or $0.43 loss per basic and diluted share for the six months ended June 30, 2012. Included in GAAP net loss for the six months ended June 30, 2013 and June 30, 2012 was stock-based compensation expense of $30.4 million and $5.3 million, respectively.

Revenue for the quarter ended June 30, 2013 was $54.7 million compared to $2.1 million for
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014  Neurocrine ... that the Company will report its second quarter 2014 ... August 6, 2014.  Neurocrine will then host a live ... and provide a Company update Thursday morning, August 7, ... Time). Participants can access the live conference ...
(Date:7/29/2014)... TORONTO , July 29, ... ESAQ), an emerging pharmaceutical company exploring drug ... novel formulations and alternative dosage forms of ... its pharmaceutical development implementing its sub-micron platform technology.  ... drugs that will address indications in diabetes ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. , The study finds that the majority ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is ... a non-profit organization providing grief camps for kids, teens, adults, ... suffering our clients experience from the death of a loved ... organization like Stepping Stones of Hope, as they provide hope ... of Hope also includes a monthly support group and a ...
(Date:7/29/2014)... app that helps headache sufferers to record the severity ... part of a Griffith research study. , A new ... looks at coping with their triggers and is being ... Behaviorial Basis of Health program. , He has developed ... the triggers of their headaches called Learning to Cope ...
(Date:7/29/2014)... most cases of cancer is to surgically remove the ... that the surgeon may fail to extract the entire ... new technique, researchers at the University of Pennsylvania have ... entire tumor in the patient, increasing the likelihood of ... dye that accumulates in cancerous tissues much more so ...
Breaking Medicine News(10 mins):Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3
... risk of dementia according to recent research. // ,People ... risk of dementia and Alzheimer’s disease. ,DHA or docosahexaenoic ... that is required for the proper functioning of the central ... issue of the Archives or Neurology. ,According to lead ...
... An Austrian study points out that the risk of developing ... results of the study done by researchers from Medical University ... ,The study found out that marathon runners have increased chances ... .Both liver spots and moles reflect a higher risk to ...
... virus boost the cancer-killing abilities of existing cancer drugs? ... on Molecular Targets and Cancer Therapeutics, in Prague, Czech ... may lead to more effective treatment options for patients ... in which malignant (cancer) cells form in the tissues ...
... law to register all health care infrastructure in the country ... // ,"The act named as the Clinical Establishment Act ... and will register all health care institutes, infrastructure and human ... in a function entitled "Public Health Initiative: PPP model"., ...
... Hobart Hospital who are attending to babies born to ... the babies are discharged from the hospital. It is ... addictions at the hospital annually., ,The director ... Peter Dargaville, said, "We see the most severely affected ...
... that more than two thirds of the Britons fearing heart ... an ambulance. //The reluctance in calling emergency help have proved ... to be the biggest killer, often killing at least one ... ,The poll was conducted under the BHF's 'Doubt Kills' ...
Cached Medicine News:Health News:Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs 2
... Sodium Hyaluronate (1.8%) viscoelastic solution combines maximum ... Rayflo maintains a deep anterior chamber and ... is ideal for routine cataract surgery but ... requiring a viscoelastic. Combine all these properties ...
... Healon5 is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average molecular ... Healon5 contains 23 mg/mL of sodium ... units of N-acetylglucosamine and sodium glucuronate ...
... is a highly retentive, dispersive viscoelastic. ... weight, low pseudoplasticity and low surface ... and excellent tissue protection. It is ... (catalog number 8065183905) or as part ...
... planning workstation is used to plan precisely ... Planning Workstation, the surgeon can simulate the ... the patient. This enables the selection of ... material waste and procedural costs. The surgeon ...
Medicine Products: